International Journal of Drug Regulatory Affairs (IJDRA)
  • Year: 2018
  • Volume: 6
  • Issue: 2

A retrospective study of Warning Letters issued by US FDA over 2015–2017

  • Author:
  • Lakshmi Ananth1,, Nirmal K. Gurbani1, Saurabh Kumar1, Bharat Gujavarti2
  • Total Page Count: 6
  • Page Number: 48 to 53

1School of Pharmaceutical Management, The IIHMR University, Jaipur, Rajasthan, 302029, India

2Greatfour Systems Private Limited, HITEC City, Hyderabad, Telangana, 500081, India

*Corresponding author. Tel.: +91-9950125228; E-mail address: lakshmi.j16@iihmr.in (L. Ananth).

Online published on 17 September, 2019.

Abstract

This paper provides contemporary climate of warning letters issued by US FDA over 2015 to 2017. With 1300$ Billion Revenue in 2017 United States stands as World's largest Pharmaceutical Market. Being the largest, diversified and due to globalization, US Pharma industry is the most competitive and critical sectors of the economy. So, exporting to the US is a great opportunity which is leveraged by many countries and US FDA was formed to check the quality standards of Medicines. Since the inception of US FDA, it has been giving many warning letters to Pharmaceutical Companies for violating regulatory guidelines. The back bone of this paper is to analyse warning letters and to identify what are the major violations in case of Pharmaceuticals.

Keywords

Form 483, Warning Letters, Regulatory Affairs, Regulatory Environment, Adulteration, Labelling Issues, Misbranding, Misleading Claims, FDA Warning Letters